Bristol-Myers subsidiary grew by 3% - correction:
This article was originally published in Clinica
Executive Summary
Sales for the first quarter for one of Bristol-Myers Squibb's subsidiaries, ConvaTec, rose 3% without compensation for the effects of the strong dollar abroad, rather than fell 3%, as was reported in a recent issue (see Clinica No 805, p 11).